Comparison of nevirapine (NVP) resistance in ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012

AIDS Research and Human Retroviruses

Volumn 20, Issue 6, 2004, Pages 595-599

  Eshleman, S H ^a   Guay, L A ^a   Mwatha, A ^b   Cunningham, S P ^a   Brown, E R ^c   Musoke, P ^d   Mmiro, F ^d   Jackson, J B ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOTHER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; UGANDA; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS TRANSMISSION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEVIRAPINE; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; TIME FACTORS; UGANDA; VIRAL PROTEINS;

EID: 3042642876     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041217518     Document Type: Article

References (15)

1. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, and Jackson JB: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999;354:795-802.
2. Jackson JB, Musoke P, Fleming T, Guay L, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, and Mmiro F: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-868.
3. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, and Sullivan JL: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998;178:368-374.
4. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, and Jackson JB: A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479-486.
5. Eshleman SH, Guay LA, Mwatha A, Brown E, Cunningham SP, Musoke P, Mmiro F, and Jackson JB: Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004;35(2):126-130.
6. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham C, Mirochnick M, Musoke P, Fleming T, Fowler MG, Mofenson LM, Mmiro F, and Jackson JB: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
7. Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, and Jackson JB: Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). J Infect Dis 2001;184:914-917.
8. Kantor R, Lee E, Johnston E, Mateta P, Zijenah L, Maldonado Y, and Katzenstein D: Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antiviral Ther 2003;8:S85.
9. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, and Whitcomb JM: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: 920-928.
10. Huang W, Wrin T, Gamarnik A, Beauchaine J, Whitcomb JM, and Petropoulos C: RT mutations that confer NNRTI resistance may also impair replication capacity. XI International HIV Drug Resistance Workshop, Seville, Spain, 2002, abstract #72.
11. Collins JA, Thompson M, and Alexander L: Competitive fitness of HIV-1 mutations that confer resistance to nevirapine. 43rd ICAAC, Chicago, IL, 2003, abstract #H-811.
12. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, and Lane HC: Relative replication fitness of a high-level 3′-azido-3′- deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr → Gly) at codon 69. J Virol 2000;74:10958-10964.
13. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, and Demeter LM: The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol 1999;73:5803-5813.
14. Little SJ, Dawson K, Hellmann NS, Richman DD, and Frost SDW: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring therapy. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 2003, abstract #115.
15. Cunningham CK, Chaix M-L, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, and Sullivan JL: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002;186:181-188.